University of Michigan Assistant Professor Brandon Ruotolo received an American Society for Mass Spectrometry 2011 Research Award this week in recognition of his accomplishments with mass spectrometry.
Ruotolo's lab focuses on using mass spec to investigate large protein complexes involved in DNA replication and contributing to protein aggregation diseases like Alzheimer's, type II diabetes, and cancer. Prior to joining the Michigan faculty in 2009, Ruotolo worked as a research fellow under Carol Robinson at the University of Cambridge.
Sponsored by Waters, the award consists of a $35,000 research grant. Awardees are selected by an independent panel of mass spectrometry researchers.
Frank Witney has been named president and CEO of Affymetrix, taking over for Kevin King, who left. Witney also will serve on the company's board of directors.
Witney was previously executive VP and chief commercial officer for Affymetrix, and for the past two years CEO and president of Dionex, which was recently bought by Thermo Fisher Scientific. He was president and CEO of Panomics before the company was acquired by Affymetrix, president and COO at Packard BioScience, and president of drug discovery tools at PerkinElmer Life Sciences after it acquired Packard.
Harvard University professor and cancer institute director Ronald DePinho has been named the next president of the University of Texas MD Anderson Cancer Center in Houston.
DePinho currently is director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and he is a professor of medicine and genetics at Harvard. He will take over the position in September for John Mendelsohn, who announced he would step down from the presidency last December. Lynda Chin, DePinho's wife and Belfer's current scientific director, also will join the faculty at UT MD Anderson.